Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer / 亚洲男科学杂志(英文版)
Asian Journal of Andrology
; (6): 107-108, 2019.
Article
ي En
| WPRIM
| ID: wpr-1009673
المكتبة المسؤولة:
WPRO
ABSTRACT
PROSPER is an international Phase III trial demonstrating the beneficial role of enzalutamide, an androgen receptor antagonist, in prolonging metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. The trial showed that the median metastasis-free survival was 21.9 months longer for those treated with enzalutamide (36.6 months) compared to those treated with placebo (14.7 months). Enzalutamide also showed prolonged time to PSA progression, PSA response, and time to initiating additional antineoplastic therapy although overall survival is not yet reached. Enzalutamide is the second antiandrogen (next to apalutamide) that has gained the United States Food and Drug Administration (US FDA) label indication for use in the setting of nonmetastatic castration-resistant prostate cancer.
النص الكامل:
1
الفهرس:
WPRIM
الموضوع الرئيسي:
Phenylthiohydantoin
/
Benzamides
/
Prostatic Neoplasms, Castration-Resistant
/
Androgen Antagonists
/
Antineoplastic Agents
/
Nitriles
المحددات:
Humans
/
Male
اللغة:
En
مجلة:
Asian Journal of Andrology
السنة:
2019
نوع:
Article